Clinical Trials in the Netherlands / NCT06346301
Recruiting Not applicable

Imagery Rescripting as a Stand-alone Treatment for OCD and BDD.

NCT06346301 · tracked via the Priya Life Science Netherlands tracker
Phase
Not applicable
Started
2023-04-21
Last updated
2024-04-04

Condition(s) studied

Obsessive-Compulsive DisorderBody Dysmorphic DisordersAnxiety Disorders

Investigational drug(s) / intervention(s)

Imagery rescripting

Imagery rescripting: In Imagery Rescripting participants imagine a different sequence of events based on missed emotional needs and rescript until needs are fulfilled. Duration of sessions is up to 90 minutes.

Study summary

The goal of this multiple baseline case series study is to test the effect of imagery rescripting (ImRs) in Obsessive Compulsive Disorder (OCD) and Body Dysmorphic Disorder (BDD).

Primary objective :The course of schema or core beliefs and change in OCD and BDD. To investigate the effectiveness of imagery rescripting on factors presumed to underlie the disorder, according to schema theory, and on OCD and BDD symptoms.

Secondary objective: The change in OCD and BDD symptoms (full questionnaire), schemata and modes, core emotions, mood, affect and obtrusiveness of intrusion.

Other objectives are research into the working mechanisms of imagery rescripting by collecting qualitative data from patients and their practitioner in a qualitative interview.

For this study, a multiple-baseline single-case experimental design (SCED) is used testing different outcome variables in 18 OCD patients and 18 BDD patients. After a variable baseline period of 3-8 weeks participants will start twice weekly with imagery rescripting for 12 sessions, followed by a 6 week follow up.

Participants will rate schema- or core beliefs and OCD or BDD severity on a visual analogue scale. In addition participants will rate core emotions, affect and obtrusiveness of the intrusion. Secondary we will asses four times questionnaires about OCD of BDD symptoms, depression and schemas en modes. After treatment participants will be interviewed about their experiences.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Meet the criteria for OCD or BDD, a primary diagnosis according to the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) * Are aged 18 and beyond * Dutch literacy * Cut-off Y-BOCS of 20 * No change in medication. Stable dose at least 6 weeks prior to study. Exclusion Criteria: * Current (hypo)mania * Active suicidal plans * Current psychosis (excluding delusional symptoms related to disorder) * Alcohol or drugs abuse as diagnosed by Diagnostic and Statistical Manual of Mental Disorders (DSM-5) * Electroconvulsive therapy in last 6 months * Neurological disorder or Intelligence Quotient \< 80

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Department of Psychiatry, AMC Amsterdam-Zuidoost North Holland Recruiting

More Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) trials in the Netherlands

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06346301 on ClinicalTrials.gov ↗ ← All trials in the Netherlands